B7-33 is a synthetic peptide derived from relaxin-2, a naturally occurring human hormone involved in tissue remodeling, anti-fibrotic activity, and cardiovascular regulation. Unlike full-length relaxin, B7-33 is a shortened, selectively engineered fragment designed to retain specific biological benefits while minimizing broader hormonal effects.
B7-33 is considered a research peptide and is not an approved pharmaceutical treatment.
What Is B7-33 ?
B7-33 is a single-chain peptide modeled from a specific region of the relaxin-2 molecule. Relaxin plays a role in connective tissue flexibility, blood vessel relaxation, and regulation of fibrosis throughout the body. The full hormone affects multiple systems, including reproductive and endocrine pathways.
B7-33 was developed to isolate relaxin’s tissue-protective and anti-fibrotic properties while avoiding its reproductive or systemic hormonal actions. This selective design is a key reason it has gained attention in research settings.
How B7-33 Works
B7-33 works by activating the RXFP1 receptor, the same receptor targeted by natural relaxin. Activation of this pathway is associated with reduced fibrosis, improved tissue remodeling, and enhanced blood vessel function.
Rather than stimulating growth or hormone release, B7-33 focuses on regulating how tissues heal and remodel after injury or chronic stress. Its effects are more regulatory than stimulatory, emphasizing balance rather than acceleration.
Potential Areas of Interest
B7-33 is commonly associated with research into:
Reduction of fibrotic tissue formation
Support for healthy tissue remodeling
Cardiovascular and vascular function
Protection against organ scarring
Connective tissue flexibility and resilience
Chronic inflammation-related tissue changes
Much of this interest comes from preclinical research examining fibrosis in organs such as the heart, lungs, kidneys, and liver.
Biochemical Characteristics
Sequence: VIKLSGRELVRAQIAISGMSTWSKRSL
PubChem CID: 318164840
Synonyms: (B7-33)H2, GTPL9321
Research Applications
B7-33 is employed in research environments to study receptor-biased signaling at the relaxin family peptide receptor 1 (RXFP1). Experimental use focuses on quantifying kinase activation profiles, extracellular matrix turnover markers, and receptor heterodimerization behavior using molecular, cellular, and histological assays.
Additional applications include evaluation of peptide-mediated modulation of matrix metalloproteinase expression, collagen organization, and signaling pathway selectivity in in-vitro systems and in-vivo animal models.
Pathway / Mechanistic Context
B7-33 demonstrates preferential activation of extracellular signal-regulated kinase (ERK1/2) signaling following RXFP1 receptor engagement, with minimal activation of cyclic AMP–dependent pathways. This signaling bias enables targeted examination of kinase-driven transcriptional and post-translational responses.
Mechanistic studies indicate that RXFP1 activation by B7-33 facilitates receptor interaction with angiotensin II type-2 receptors, contributing to downstream modulation of matrix-associated signaling networks. These interactions are assessed using phosphorylation assays, gene expression profiling, and extracellular matrix component analysis.
Preclinical Research Summary
In preclinical animal and cellular studies, B7-33 has been investigated for its effects on extracellular matrix composition, metalloproteinase regulation, and vascular signaling endpoints. Experimental outcomes are measured using histological staining, biochemical quantification, and receptor signaling assays.
Additional research explores the incorporation of B7-33 into biomaterial coatings to evaluate cellular responses to implanted substrates, focusing on matrix deposition and capsule formation in controlled experimental systems.






Reviews
There are no reviews yet.